The label covers adults and children aged 12 and older with obesity, and adults with overweight and at least one weight-related condition. It was first approved in the United States in 2012, is a controlled substance in schedule IV, and is not a GLP-1 medicine.1
What it is
The label calls phentermine a sympathomimetic amine anorectic, a stimulant-type drug that reduces appetite. On its own it is used for a limited time to speed weight loss.1,2 Topiramate on its own is used to treat certain seizures and to prevent migraine headaches.3 In Qsymia both are in one extended-release capsule, and the label writes each strength as a pair: phentermine in milligrams first, topiramate second.
How the dose is set
Qsymia is taken once a day in the morning, with or without food; the label advises against evening doses because of insomnia. The schedule has two checks built in.1
- Start at 3.75 mg/23 mg for 14 days, then take 7.5 mg/46 mg, the recommended dose.
- After 12 weeks on 7.5 mg/46 mg, an adult who has not lost at least 3% of starting weight moves to 11.25 mg/69 mg for 14 days and then to 15 mg/92 mg.
- After 12 weeks on 15 mg/92 mg, an adult who has not lost at least 5% should stop, since meaningful weight loss is then unlikely.
The top dose is not stopped all at once: the label asks for a gradual stop to avoid a possible seizure. People with moderate or severe kidney impairment or moderate liver impairment stay at 7.5 mg/46 mg at most.1
What it did in trials
Two one-year trials in adults support the approval.1
- Obesity. Adults who started at an average of about 115 to 119 kg lost 10.9% on 15 mg/92 mg and 5.1% on 3.75 mg/23 mg, against 1.6% on placebo. At least 10% was lost by 47%, 19% and 7%.
- Obesity or overweight with a related condition. Adults who started at about 103 kg lost 9.8% on 15 mg/92 mg and 7.8% on 7.5 mg/46 mg, against 1.2% on placebo. At least 5% was lost by 70%, 62% and 21%.
For context, Wegovy 2.4 mg lowered weight by 14.9% over 68 weeks in its own trial; the two were never compared directly.4
Side effects and warnings
The most common side effects differ from those of the GLP-1 medicines. On the top dose, tingling of the skin, known as paresthesia, was reported by 20% against 2% on placebo. Dry mouth was reported by 19% against 3%, constipation by 16% against 6% and a change in taste by 9% against 1%.1 Heart rate also rises: a rise of more than 10 beats per minute at some point was seen in 56.1% on the top dose against 42.1% on placebo.1
The most serious warning concerns pregnancy. Topiramate taken in the first trimester raises the risk of major birth defects, including cleft lip and cleft palate. Qsymia must not be taken in pregnancy, and for anyone who can become pregnant the label recommends a negative pregnancy test before starting and monthly during treatment, plus effective contraception. For that reason it is available only through a restricted program, a REMS. It is also ruled out with glaucoma, an overactive thyroid and within 14 days of a monoamine oxidase inhibitor.1
Qsymia in eight lines
| Fact | Qsymia |
|---|---|
| Active ingredients | Phentermine and topiramate |
| First U.S. approval | 2012 |
| Form | Extended-release capsule, once a day |
| Usual dose | 7.5 mg/46 mg |
| Top dose | 15 mg/92 mg |
| Controlled substance | Schedule IV |
| Pregnancy | Ruled out; monthly tests advised |
| Youngest age | 12 |
QSYMIA prescribing information, DailyMed version of April 24, 2026.1
Related terms
Contrave is the other combination tablet for weight, built from naltrexone and bupropion. Birth control also comes up with the GLP-1 medicines, for a different reason: our page on Zepbound and birth control explains why the pill may work less well after a dose increase.
Sources
- QSYMIA (phentermine and topiramate extended-release capsules) prescribing information. Vivus LLC; DailyMed, U.S. National Library of Medicine, version published April 24, 2026; sections 1, 2, 4, 5, 6.1, 8.1 and 14. dailymed.nlm.nih.gov
- MedlinePlus. Phentermine. U.S. National Library of Medicine; last revised December 15, 2024, read November 20, 2026. medlineplus.gov
- MedlinePlus. Topiramate. U.S. National Library of Medicine; last revised May 15, 2026, read November 20, 2026. medlineplus.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov
Related analyses
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Wegovy weight loss chart: the trial results week by week, in your own weight
Zepbound and birth control pills: the 4-week rule, with your dates
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Log each capsule and your weight, and see the 12-week checks coming.
Open Dose Insider